OOIR: Observatory of International Research

Papers

(The median citation count of JAMA Neurology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Diplopia and Ptosis in an Older Woman	660
Somebody to Love	452
Optimizing the Time Course of Risks and Benefits of Acute Dual Antiplatelet Therapy for Stroke Prevention	443
Error in Author Name	313
Early vs Delayed Extubation After Thrombectomy for Acute Ischemic Stroke	270
Risk of Dementia in Individuals With Emergency Department Visits or Hospitalizations Due to Cannabis	251
Itching Frequency and Neuroanatomic Correlates in Frontotemporal Lobar Degeneration	251
Early Access to First-Seizure Clinics, Subsequent Outcomes, and Factors Associated With Attendance	241
Substantia Nigra Pathology, Contact Sports Play, and Parkinsonism in Chronic Traumatic Encephalopathy	234
Ghrelin for Neuroprotection in Post–Cardiac Arrest Coma	233
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation	227
Origin of Transthyretin in Cerebral Amyloid Angiopathy	218
Rizatriptan vs Placebo for Attacks of Vestibular Migraine	216
Automated Imaging Differentiation for Parkinsonism	215
Equipping AI for Unbiased and Inclusive Neurology	200
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation	198
A Call to Action to Address Sex Differences in Alzheimer Disease Clinical Trials	195
Alternate Hemibody Hyperkinetic and Hypokinetic Movement Disorders Due to Strategic Lesions in Cerebral Toxoplasmosis	186
Reinterpreting Clinical Trials in Children With Multiple Sclerosis Using a Bayesian Approach	176
JAMA Neurology	174
Functional Outcomes in Conservatively vs Surgically Treated Cerebellar Infarcts	171
JAMA Neurology	159
Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease	158
Is It Really Itching?	147
The Neurologist’s Imperative in Brain Death	145

External Carotid Artery Angioplasty Based on Ultrahigh-Resolution Photon-Counting CTA	144
Anticoagulation and Antiplatelet Therapy in Patients With Atrial Fibrillation and Atherosclerosis	138
Time From Hospital Arrival Until Endovascular Thrombectomy and Patient-Reported Outcomes in Acute Ischemic Stroke	131
Endovascular Therapy for Basilar Occlusions—The ATTENTION Trial	128
Thrombolysis With Tenecteplase for Minor Disabling Stroke	123
Time to Change the Current Clinical Classification of Multiple Sclerosis?	122
Teleneurorehabilitation and Motor and Nonmotor Symptoms and Quality of Life in Parkinson Disease	121
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis	120
Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers	119
Histologic Anatomy of Neurocysticercosis	117
Error in Abstract	117
Error in Additional Contributions	117
Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation	117
Error in Figure	116
Spontaneous AICA Dissection Presenting With Isolated Audiovestibular Loss	116
Wind Swirl Pattern on Density Spectral Array in Anti-GABAB Receptor Encephalitis With Amnestic Seizures	114
Functional Seizures—A Critical Comorbidity Overlooked in Epilepsy Research—Reply	114
Sleep Recording for the Diagnosis and Treatment of Paraplegia	113
Is It Really Itching?—Reply	107
Association of Cardiovascular Events With Spouse’s Subsequent Dementia	107
Spinal Cerebrospinal Fluid Leak Mimicking a Cerebellopontine Angle Tumor	105
JAMA Neurology	104
Retinal Hemorrhage Associated with Human Granulocytic Anaplasmosis	103
Tackling the Unmet Therapeutic Needs in Nonsurgical Treatments for Epilepsy	103
β-Amyloid Positron Emission Tomography Use Across Medicare Administrative Contractor Regions	103
Interhemispheric Bullet Migration—A Surgical Dilemma	102
Tilting at Treadmills—Pitfalls and Potential of Dementia Prevention Trials	99
Seizure Frequency Trends Over Time in Treatment-Resistant Focal Epilepsy	98
Five Years of Ublituximab in Multiple Sclerosis	96
Catheter Ablation and Oral Anticoagulation for Secondary Stroke Prevention in Atrial Fibrillation	90
Risk Factors Associated With Late-Onset Epilepsy in Dementia and Mild Cognitive Impairment	86
Intra-Arterial Tenecteplase After Successful Reperfusion in Large Vessel Occlusion Stroke	86
N-Acetylcysteine for Hereditary Cystatin C Amyloid Angiopathy	86
Do Neurologists Need a Goldwater Rule?	86
Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease	85
Contribution of Somatic Ras/Raf/Mitogen-Activated Protein Kinase Variants in the Hippocampus in Drug-Resistant Mesial Temporal Lobe Epilepsy	85
Prourokinase vs Standard Care for Patients With Mild Ischemic Stroke	84
Role of the X Chromosome in Alzheimer Disease Genetics	84
Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease	83
GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias	82
Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology	82
Endovascular Stroke Thrombectomy for Patients With Large Ischemic Core	82
JAMA Neurology	81
Error in Text	78
Error in Figures	78
Perceived CTE and Suicidality—Is Perception Reality?	78
Error in Key for Figure 3	77
Peripheral-Type Facial Paralysis and Unilateral Hemisphere Hemorrhage	77
A Rare Neurological Presentation of Kikuchi-Fujimoto Disease	76
Bibrachial Amyotrophy Due to Spontaneous Spinal Cerebrospinal Fluid Leak	75

AI Devices in Neurology—Moving From Diagnosis to Prognosis	74
A 62-Year-Old Man With Progressive Limb Weakness, Involuntary Movements, and HyperCKemia	74
Magnetic Resonance Imaging Features of GABA-A Receptor Antibody-Mediated Encephalitis	74
“The Triage of Privilege” Factual Concerns	72
The New Era of Automated Electroencephalogram Interpretation	71
Visualization of Parkinsonian Tongue Tremor on Ultrasonography	71
Functional Impairment in Individuals With Prodromal or Unrecognized Parkinson Disease	70
IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease	69
Error in Author’s Name	69
Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients	68
Behavioral Compared With Drug Therapy for Overactive Bladder Symptoms in Parkinson Disease	68
Ongoing Challenges in the Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease	68
Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers	67
Expanding Clinical Spectrum of Anti-GQ1b Antibody Syndrome	67
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis	67
Comparison of Perinatal Outcomes for Women With and Without Epilepsy	66
Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke	66
Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis	65
Minimally Invasive Surgery vs Medical Management Alone for Intracerebral Hemorrhage	63
Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome	63
The Semont-Plus Maneuver or the Epley Maneuver in Posterior Canal Benign Paroxysmal Positional Vertigo	62
The Choreoathetotic Movement of Paroxysmal Nonkinesigenic Dyskinesia	61
Livedo Reticularis—A Presenting Sign of Neuromyelitis Optica Spectrum Disorder	61
JAMA Neurology Peer Reviewers in 2021	61
Benefits and Risks of Periconceptional Folic Acid Supplementation—Reply	60
Burden of Central Nervous System Cancer in the United States, 1990-2021	60
Error in Title	60
SARS-CoV-2 Vaccination and Neuroimmunological Disease	60
Life Expectancy for Patients With Sporadic Creutzfeldt-Jakob Disease	58
Cerebral Amyloid Angiopathy—How to Translate Updated Diagnostic Criteria for This Multifaceted Disorder to Clinical Practice?	57
Abdominal Clonus in the Setting of a T5 Spinal Cord Injury	57
Benefits and Risks of Periconceptional Folic Acid Supplementation	56
Possible Explanations for Hearing Loss in Parkinson Disease	56
Choosing the Best Antiseizure Medication—Can Artificial Intelligence Help?	56
Repairing Our View of Dementia	55
Cognitive Behavioral Therapy for Veterans With Comorbid Posttraumatic Headache and Posttraumatic Stress Disorder Symptoms	55
Reimagining the Treatment of Distal and Medium Vessel Occlusion Strokes	55
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis	55
Autism and Parkinsonism—Terminology and Confounding	55
IWG and AA Criteria—Where the Differences Matter—Reply	54
Brain Imaging Biomarkers and Cognitive Outcomes in a Multidomain Lifestyle Intervention	54
Alzheimer Disease Blood Biomarkers in Patients With Out-of-Hospital Cardiac Arrest	54
Expanding the Prion Paradigm to Include Alzheimer and Parkinson Diseases	54
Addition of Nonauthor Collaborators and a Supplement	53
Adverse Childhood Experiences, Toxic Stress, and Trauma-Informed Neurology	53
Coma Prognostication After Acute Brain Injury	53
Association Between Acute Myocardial Infarction and Cognition	53
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography	53
Novel Meningoencephalomyelitis Associated With Vimentin IgG Autoantibodies	53
Monogenic Stroke—Can We Overcome Nature With Nurture?	51
JAMA Neurology	51
Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis—Variations in Real-World Experience—Reply	50
The Perils and Pitfalls of Global Engagement	50
Views From Both Sides of the White Coat	49
Error in Author Affiliation	48
Errors in Figure 2 and the Short Title	48
How Is the X Chromosome Involved in Alzheimer Disease?	48
Transcarotid Artery Revascularization for Stroke Prevention—Multiple Elephants in the Room	47
Gantenerumab in Dominantly Inherited Alzheimer Disease—Reply	47
Chronic Immune Peripheral Nerve Myelinopathies—A Plea for Precision	45
Modern Neurology Training Is Failing Outpatients	45
The Self-Test	44
Medical Forecasting—A Skill Set Worthy of Attention	44
Exome Sequencing and the Identification of New Genes and Shared Mechanisms in Polymicrogyria	44
Structural Inequities for Historically Underserved Communities in the Adoption of Stroke Certification in the United States	44
A Test of the Alzheimer Disease Framework—Did It Pass?	44
Incidence and Risk Factors of Epilepsy Among Older Adults in the US Medicare Population	44
Association of Aortic Stiffness and Pressure Pulsatility With Global Amyloid-β and Regional Tau Burden Among Framingham Heart Study Participants Without Dementia	44
GLP-1 RAs for Idiopathic Intracranial Hypertension—Time for a Trial	44
Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors	43
Dietary Patterns and Indicators of Cognitive Function	43
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis	43
Maternal Pregnancy Outcomes and Offspring Risk of Adult-Onset Multiple Sclerosis	42
Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants	42
Hypertension With High-Risk Features in Cryptogenic Stroke	42
One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China	42
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease	41
Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis	41
Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage	41
Visual Impairment as a Modifiable Risk Factor in Dementia Prevention and Management	40

JAMA Neurology	40
Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios	40
TDP-43 Accumulation Within Intramuscular Nerve Bundles of Patients With Amyotrophic Lateral Sclerosis	40
Error in Figures 2 and 3	39
Bilateral Complete Ophthalmoplegia in a 50-Year-Old Man	39
A 51-Year-Old Woman With Abnormal Corpus Callosum Signal	39
JAMA Neurology	39
Acute Ischemic Stroke Care Quality Improvement	39
Multimodal Neuroimaging of Intimal Flap in a Basilar Artery Dissection	38
Directly Isolated Allogeneic Virus–Specific T Cells in Progressive Multifocal Leukoencephalopathy	37
2024 Diagnostic Criteria for Multiple Sclerosis—A Unified Approach	37
Development and Validation of a Deep Learning Model for Predicting Treatment Response in Patients With Newly Diagnosed Epilepsy	37
Error in Open Access Status	37
Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis	37
Venture Capital Investment in Neurology Companies	36
Risks of Expanded Medicare Coverage of Carotid Artery Stenting	36
Multisite Skin Biopsies vs Cerebrospinal Fluid for Prion Seeding Activity in the Diagnosis of Prion Diseases	36
Advocating for Demonstration of Disease Modification—Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly?	36
Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease	35
Genome Sequencing After Exome Sequencing in Pediatric Epilepsy	35
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine	35
Discussion on the Application of Rapid Immunoblot Assay for AQP4-IgG Detection	35
Neurologic Complications of Smallpox and Monkeypox	35
Cerebrospinal Fluid Biomarkers for Alzheimer Disease Among Patients With Dementia	34
Recurrent Ischemic Stroke in Patients With Atrial Fibrillation While Receiving Oral Anticoagulants	34
Asymptomatic Carotid Stenosis—Is Medical Therapy Enough?	34
An Acetylcholine M₁ Receptor–Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment	34
White Matter Tract Density Index Prediction Model of Overall Survival in Glioblastoma	34
Endovascular Thrombectomy Treatment Effect in Direct vs Transferred Patients With Large Ischemic Strokes	34
Physical Frailty, Genetic Predisposition, and Incident Parkinson Disease	33
Immediate- or Delayed-Intensive Statin in Acute Cerebral Ischemia	33
Targeting Sleep and Circadian Function in the Prevention of Alzheimer Disease	33
Risk of Stroke, Death, and Myocardial Infarction Following Transcarotid Artery Revascularization vs Carotid Endarterectomy in Patients With Standard Surgical Risk	33
Risk Factors for Young-Onset Dementia in the UK Biobank	33
CT Perfusion Imaging After Selection for Late-Window Endovascular Stroke Treatment	33
Batoclimab vs Placebo for Generalized Myasthenia Gravis	33
ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels	32
Butter Yellow—A Soft Hue With Neurological Implications	32
Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms	32
Entering Medicine as a Physician and a Patient	32
A Funeral for a Neurologist	32
Effect of Irrigation Fluid Temperature on Recurrence in the Evacuation of Chronic Subdural Hematoma	32
Intramedullary Hemorrhage Causing Quadriplegia in the Setting of a Type B Aortic Dissection	32
Paused—A Residency Interrupted	32
A New Dystonia Phenotype in Wilson Disease	32
Remembering the Physician’s Humanity—Physicians Are Humans Too	32
What Should the Goals Be for Diverse Recruitment in Alzheimer Clinical Trials?	32
Association Between Use of Angiotensin Receptor Blockers and Incidence of Epilepsy in Patients With Hypertension—Reply	32
Rethinking the Menopause Transition and Multiple Sclerosis Progression	31
Safety and Efficacy of Staged, Bilateral Focused Ultrasound Thalamotomy in Essential Tremor	31
JAMA Neurology Editorial Fellowship	31
Association of Tourette Syndrome and Chronic Tic Disorder With Violent Assault and Criminal Convictions	31
Pattern of Recurrent Nontraumatic Intracerebral Hemorrhage—Reply	30
Postmortem Assessment of Olfactory Tissue Degeneration and Microvasculopathy in Patients With COVID-19	30
E-Cigarettes and Stroke Risk—Present Uncertainties and Future Directions	30
Kelch-Like Protein 11 Antibody-Associated Paraneoplastic Encephalitis	30
Quality Improvement Intervention for Reducing Acute Treatment Times in Ischemic Stroke	30
Embedded Human Closed-Loop Deep Brain Stimulation for Tourette Syndrome	29
Gene Therapy vs Cochlear Implantation in Restoring Hearing Function and Speech Perception for Individuals With Congenital Deafness	29
Uniform Amyloid Thresholds Across Populations	29
JAMA Neurology Peer Reviewers in 2025	29
Lecanemab Treatment in a Specialty Memory Clinic	29
Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers	29
Bilateral Calcification of the Meckel Cave Causing Hemicrania Continua	28
Error in Figure 2B	28
Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease—Reply	28
Error in Title	28
Anticoagulation in ESUS—Back From the Dead?	27
Error in Figure 1	27
Central Retinal Artery Occlusion With Cilioretinal Artery Sparing After Semaglutide Injection	27
Direct-Acting Oral Anticoagulants and Antiseizure Medications for Atrial Fibrillation and Epilepsy and Risk of Thromboembolic Events	27
Error in Figures	27
Higher Educational Attainment and Accelerated Tau Accumulation in Alzheimer Disease	27
Iatrogenic Cerebrospinal Fluid–Venous Fistula	27
How SAFE Is Real-world Use of Spinal Cord Stimulation Therapy for Chronic Pain?	27
Effect of Bypassing the Closest Stroke Center in Patients with Intracerebral Hemorrhage	27
Trends in AVM-Associated Intracranial Hemorrhage in the United States, 2000-2019	27
Cavernous Sinus Dural Arteriovenous Fistula With Ocular Congestion and Proptosis	26
Paramagnetic Rim Lesions and Development of Clinical MS in Radiologically Isolated Syndrome	26
Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease	26
Combined Physiotherapy and Cognitive Behavioral Therapy for Functional Movement Disorders	25
Levodopa Content of Mucuna pruriens Supplements in the NIH Dietary Supplement Label Database	25
JAMA Neurology—The Year in Review, 2023	25
Gadolinium-Enhanced Aneurysm Wall Imaging and Risk of Intracranial Aneurysm Growth or Rupture	25
JAMA Neurology	25
Risk of Inflammatory Central Nervous System Diseases After Tumor Necrosis Factor–Inhibitor Treatment for Autoimmune Diseases	25
Pneumorrhachis From Esophageal Perforation Due to Cervical Osteophyte	24
Pain Phenotypes and Pain Multimorbidity Among Medicare Beneficiaries With Cerebral Palsy	24
Do the Benefits of Blood Pressure Control in ICH Outweigh the Risks?	24
Sex Differences in Case-Fatality Rates of Stroke—Reply	24
JAMA Neurology	24
Errors in the Results	24
The Cynicism of the Seronegative	24
Functional Impairment Preceding Parkinson Disease Diagnosis—What’s in a Prodrome?	24
Immortal Time Bias and Nonlinear Stroke Recurrence Risk—Reply	24